Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Fort Worth, Texas. The company focuses on developing therapies for difficult-to-treat cancers by targeting biological pathways that promote tumor growth and resistance. Its lead product candidate, elraglusib, is a small-molecule inhibitor currently in clinical trials for metastatic pancreatic cancer and various pediatric malignancies.
Financial Statements
In thousands, USD
FY 2025
FY 2024
FY 2023
FY 2022
Selling, General & Administrative Expenses
12,203
6,484
3,265
3,820
Research & Development Expenses
10,293
18,676
21,708
16,387
Operating Profit
(22,495)
(25,161)
(24,974)
(20,207)
Interest and Investment Income
288
222
353
27
Interest Expense
(20)
(19)
(44)
(16)
Non-Operating Income
—
(2,328)
(80)
37
Total Non-Operating Income
267
(2,125)
229
47
Income Before Provision for Income Taxes
(22,228)
(27,285)
(24,745)
(20,159)
Consolidated Net Income
(22,228)
(27,285)
(24,745)
(20,159)
Net Income Attributable to Common Shareholders
(22,228)
(27,285)
(24,745)
(20,159)
Basic EPS
-1.06
-3.26
-17.24
-16.65
Diluted EPS
-1.06
-3.26
-17.24
-16.65
Basic Weighted Average Shares Outstanding
21,022
8,373
1,435
1,211
Diluted Weighted Average Shares Outstanding
21,022
8,373
1,435
1,211
Shares Outstanding
23,245
19,532
1,691
1,691
FY 2025
FY 2024
FY 2023
FY 2022
Cash and Cash Equivalents
13,159
8,642
2,959
20,449
Total Cash and Cash Equivalents
13,159
8,642
2,959
20,449
Other Current Assets
484
566
37
34
Total Current Assets
13,643
9,208
2,996
20,483
Other Long-Term Assets
392
111
—
—
Total Assets
14,036
9,318
2,996
20,483
Accounts Payable
1,524
1,921
3,422
2,131
Accrued Expenses
4,156
6,810
3,499
2,214
Other Current Liabilities
27
71
—
—
Total Current Liabilities
5,707
8,803
6,921
4,345
Other Long-Term Liabilities
405
412
1,523
1,306
Total Long-Term Liabilities
405
412
1,523
1,306
Total Liabilities
6,112
9,214
8,444
5,651
Common Stock
0
0
0
0
Additional Paid-in Capital
162,532
132,484
5,468
5,044
Retained Earnings
(154,608)
(132,380)
(105,095)
(80,350)
Total Common Shareholders' Equity
7,924
104
(99,627)
(75,305)
Minority Interests and Other
—
—
94,178
90,138
Total Shareholders' Equity
7,924
104
(5,448)
14,832
Total Liabilities and Shareholders' Equity
14,036
9,318
2,996
20,483
FY 2025
FY 2024
FY 2023
FY 2022
Net Income
(22,228)
(27,285)
(24,745)
(20,159)
Share-Based Compensation Expense
6,047
1,996
424
654
Other Adjustments
20
2,347
123
(20)
Changes in Accounts Payable
(513)
(1,501)
1,291
586
Changes in Accrued Expenses
(2,726)
3,241
1,285
1,171
Changes in Other Operating Activities
193
(640)
(3)
(25)
Cash from Operating Activities
(19,206)
(21,843)
(21,625)
(17,794)
Issuance of Short-Term Debt
—
200
—
—
Repayments of Short-Term Debt
—
(200)
—
—
Net Issuance / (Repayments) of Short-Term Debt
—
0
—
—
Issuance of Long-Term Debt
—
5,500
—
—
Net Issuance / (Repayments) of Long-Term Debt
—
5,500
—
—
Issuance of Common Shares
24,027
23,957
—
—
Net Issuance / (Repurchases) of Common Shares
24,027
23,957
—
—
Issuance of Preferred Shares
—
—
4,135
19,256
Net Issuance / (Repurchases) of Preferred Shares
—
—
4,135
19,256
Other Financing Activities
(303)
(1,931)
—
—
Cash from Financing Activities
23,724
27,526
4,135
19,256
Increase / (Decrease) in Cash, Cash Equivalents and Restricted Cash